STUDY: Cross-sex hormones increase heart disease risk in transvestites by 93%

Over the last fifteen years, a new industry has emerged, one that preys on the psychology of young adults and children, one that destabilizes, deforms and castrates people, with no regard for medical ethics. A new study finds that cross-sex hormones increase one’s risk of heart disease by 93%. These cross-sex hormones are the one-size-fits-all “treatment” for young adults and children who are confused about their gender identity.

Transgender clinics are harming patients for life, in more ways than one

In 2007, the United States’ first transgender youth clinic opened up in Boston, Massachusetts. Since then, at least forty other transgender youth clinics have opened up across the United States. These clinics see patients who are confused, lonely, autistic and/or struggling with mental and emotional difficulties. These clinics see patients who are seeking a sense of belonging, identity and validation for their feelings and urges.

However, these clinics do not properly counsel and guide children to their innate gender. The counselors and doctors are not trained to deal with the underlying endocrine disruption and its hormonal impact during puberty. The providers spend very little time with patients and do not address the psychology behind sexual desires, and how these urges affect one’s expression, appearance and view of self. These clinics do not address the external influences, the belonging factor, or the social contagion that often drives kids to make such dire conclusions about their body and identity.

Instead, these clinics are designed to automatically validate the feelings of young adults and children and go along with their desires for permanent hormonal castration and/or genital mutilation. If a patient is unhappy about their body, their image, or their identity, the counselors and doctors work together to affirm the gender of the patient’s choosing. The protocol to achieve these goals includes cross-sex hormones that validate the dysphoria and further the hormonal disruption in the body.

To make matters worse, the “gender-affirming care” that is prescribed so liberally today cannot be challenged, even when it causes further harm to the patient. Second opinions are not allowed and are often outlawed. Doctors who dissent to “gender affirming care” are routinely ostracized, even when they see the abuses of the transgender industry firsthand.

Cross-sex hormone “therapies” cause heart disease and Type-2 diabetes

These cross-sex hormone therapies are causing serious physical issues within the patient’s body. One of the greatest risks is heart disease. Males who take feminizing hormones are 93 percent more likely to suffer from heart disease than other men who do not take the drugs. Likewise, female transvestites who take testosterone are 63 percent more likely to suffer heart disease than other women who do not take the drugs. These are the results of a new study published in the European Journal of Endocrinology, which were also presented at the Annual Meeting of the European Association for the Study of Diabetes.

Male transvestites who take estrogen see increased fat mass and lower lean body mass. This increase in estrogen is associated with an increased risk of autoimmune disease, inflammation and Type-2 diabetes. The research builds upon a 2021 study that found a risk of myocardial infarction and stroke for men trying to transition to women.

Lead author Dr. Dorte Glintborg from Denmark’s Odense University Hospital wrote that “epidemiological studies in transgender women reported increased risk of acute myocardial infarction and stroke during feminizing treatment, whereas long-term, controlled studies regarding feminizing treatment and risk of arterial CVD are lacking.” Glintborg’s team tracked the health of 2,671 transvestites from Denmark over a five-year period. A total of 1,270 women and 1,402 men were studied, with the average age of 26 and 22, respectively. The transvestites were compared to a control group of 26,700 people and monitored for heart disease.

“Cardiovascular and metabolic outcomes were more prevalent in transgender persons compared to controls. Gender-affirming hormone therapy exposure could contribute to the elevated cardiovascular risk in transgender men, assigned female at birth,” the researchers concluded. “Future studies will be able to bring further knowledge regarding mechanisms for higher cardiovascular risk in transgender men and women.” This study is frightening, considering the young age of the participants in this study and the prevalence of heart disease.

Sources include:

TheBlaze.com

NaturalNews.com

TandFOnline.com

NaturalNews.com

Academic.oup.com

FindResearcher.sdu.dk [PDF]